Ser754

Site Information
GsGDsQLsAssRSES SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 14736386
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 )
Disease tissue studied:	luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 3 , 4 , 5 ) , non-small cell lung cancer ( 3 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 ) , non-small cell large cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , Cal-12T (pulmonary) ( 5 ) , Calu-3 (pulmonary) ( 4 ) , GM00130 (B lymphocyte) ( 8 ) , HCC44 (pulmonary) ( 5 ) , HCC827 (pulmonary) ( 4 ) , HeLa (cervical) ( 2 , 7 ) , lung ( 3 , 4 , 5 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 5 ) , NCI-H1650 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H1734 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 3 ) , NCI-H1975 (pulmonary) ( 4 ) , NCI-H2106 (pulmonary) ( 4 ) , NCI-H2405 (pulmonary) ( 5 ) , NCI-H358 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 3 )

Upstream Regulation
Treatments:	ionizing_radiation ( 8 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
7	Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
8	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info